ravulizumab
Astrazeneca
[]
more data from the phase 3 champion-nmosd study evaluating ravulizumab in nmosd was presented at the 2022 ectrims congress. we covered it here 
Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible. #MindMoments